

- **02.01.23 - AviadoBio Announces Appointment of Jeff Goater as Chair of the Board of Directors ([Pharmtechfocus](#))**
 - Currently, Mr. Goater serves as a Venture Partner at The Column Group and Interim CEO of Atavistik Bio. In his last position as CEO of Surface Oncology, he fostered an award-winning culture, advanced four programs into clinical development, completed its initial public offering, and secured multiple strategic collaborations, including a transformative partnership with GlaxoSmithKline. Prior to his time at Surface, Mr. Goater served as Chief Financial Officer of Voyager Therapeutics where he was a member of the founding management team. Previously, he spent nearly a decade in investment banking, most recently as a Managing Director at Evercore Partners, advising on more than \$100 billion in strategic transactions in the biopharma industry.
- **02.01.23 - Avectas announces the appointment of Dr. Ann Brady as Chief Business Officer ([PR](#))**
 - Dr. Brady has been a member of Avectas' Board of Directors since 2016. She will continue to serve on the Board as an executive Director whilst taking on the full-time CBO role. Ann most recently served as President, Theravance Biopharma Ireland and previously held senior executive roles at Shire, plc and élan Corporation, plc.
- **01.31.23 - Rallybio Corporation Appoints Jonathan I. Lieber as CFO ([Streetinsider](#))**
 - Mr. Lieber brings more than 30 years of experience as a CFO for public and private life sciences companies and an investment banker. Most recently, he served as the CFO of Applied Genetic Technologies Corporation (AGTC), a publicly traded biotechnology gene therapy company focused on rare diseases, where he led all capital raising activities and was responsible for accounting and finance, human resources, investor relations, information technology and project management. Prior to AGTC, he was a Managing Director at Danforth Advisors,. Previously, Mr. Lieber served as CFO at firms including Histogenics, a publicly traded cell therapy company, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Mr. Lieber began his career in healthcare as an investment banker at Salomon Brothers / Salomon Smith Barney and SG Cowen.
- **01.31.23 - Ocugen Appoints Quan A. Vu as Chief Business Officer ([PR](#))**
 - Previously serving Chief Operating Officer/Chief Business Officer for 180 Life Sciences, and since 2019, he has provided interim CFO/CBO/CEO consulting services through his own consulting firm, Melius BioPharma Consulting. Mr. Vu began his career in healthcare investment banking and then held leadership roles of increasing responsibility at Opiant Pharmaceuticals, Impax Laboratories, Anthem, and Amgen.
- **01.31.23 - Carisma Therapeutics Appoints Leading Solid Tumor Immunotherapy Expert Padmanee Sharma, MD, Ph.D. to Scientific Advisory Board ([PR](#))**
 - Dr. Sharma is an immunologist and professor in the departments of Genitourinary Medical Oncology and Immunology, Associate VP of Immunobiology, and the T.C. and Jeanette D. Hsu Endowed Chair in Cell Biology at The University of Texas MD Anderson Cancer Center. She joins atr a pivotal time as Crisma advanced CAR-M products through the clinic.
- **01.30.23 - Eric Lander to return to Broad Institute, one year after White House exit over bullying allegations ([Endpts](#))**
 - Eric Lander is returning to the Broad Institute, the prestigious genomic research center he helped launch and led for 16 years, a year after he resigned from the White House's top science position following accusations of demeaning and disrespectful conduct toward subordinates. Todd Golub, who succeeded Lander as Broad's director, announced Lander's return, early next month, on the institute's intranet. Lander will also resume the tenured faculty positions he left behind at MIT and Harvard, Golub added.
- **01.30.23 - Ring Therapeutics Announces Appointment of Industry Veteran Christopher Wright, M.D., Ph.D. as Chief Medical Officer, Head of Translational Research ([PR](#))**
 - Prior to joining Ring, Dr. Wright served as Chief Medical Officer of AavantiBio, Inc., a gene therapy company which was recently acquired by Solid Biosciences. Previously, Dr. Wright served as Chief Medical Officer at Cycleron, and Senior Vice President/Chief Development Officer at Ironwood Pharmaceuticals. Before Ironwood, Dr. Wright held numerous executive positions at pharma companies including Axcella Health, Inc. and Vertex Pharmaceuticals. Prior to his industry roles, Dr. Wright was an Associate Professor of Neurology at Harvard Medical School and a board-certified practicing neurologist at Brigham and Women's Hospital for 20 years. Dr. Wright earned an A.B. in biochemical sciences from Harvard University, an M.D. and MMSc. from Harvard Medical School and a Ph.D. in neurosciences from Vrije University in the Netherlands. He currently serves on the Board of Directors at Alkermes plc, and as Scientific Advisor at Cycleron Therapeutics, Inc.
- **01.25.23 - Vir Biotechnology Announces Retirement of CEO George Scangos, Ph.D.; Appoints Marianne De Backer, MSc, Ph.D., MBA, as Successor ([PR](#))**
 - George Scangos, Ph.D., will retire from his position as Chief Executive Officer (CEO), effective April 3, 2023. The Company's Board of Directors has appointed industry veteran Marianne De Backer, MSc, Ph.D., MBA, currently Executive Vice President, Head of Pharmaceuticals Strategy, Business Development and Licensing/Open Innovation, and Member of the Executive Committee for Bayer Pharmaceuticals, as his successor, effective April 3, 2023. She will also join Vir's Board of Directors. Upon his retirement as CEO, Dr. Scangos will serve in an advisory role to Dr. De Backer through June 2, 2023 and will continue providing strategic counsel to Vir as a member of the Board of Directors. Dr. Scangos has served as Vir's President and CEO, and as a member of the Board of Directors since January 2017.
- **01.23.23 - Codexis Announces Appointment of Sri Ryali as Chief Financial Officer ([PR](#))**
 - Most recently, Mr. Ryali served as the Chief Financial Officer of Eiger BioPharmaceuticals, Inc., a publicly traded, commercial-stage company, where he was responsible for finance, investor relations and other general and administrative functions during a period when the company initiated multiple late-stage clinical trials and launched its first commercial product in the United States and Europe. Prior to Eiger BioPharmaceuticals, Mr. Ryali held roles of increasing responsibility at Aimmune Therapeutics, Inc., most recently serving as Vice President of Finance. Prior to this, he was Senior Director, Financial Planning and Analysis at Jazz Pharmaceuticals, plc. and held a series of different finance-related positions of increasing responsibility at Onyx Pharmaceuticals, Inc. and Amgen Inc.

- **01.19.23 - Normunity Appoints Olga Granaturova as Chief Operating Officer and Chief Business Officer ([PR](#))**
 - She joins Normunity after serving as co-founder and Chief Operating Officer of Parthenon Therapeutics, a biotech company creating a novel class of anti-cancer therapies. Based on her business leadership role at Parthenon, as well as serving as VP of business development at Evotec and founder and managing partner of the life sciences consulting firm, LENUS Group, she has hands-on experience in company creation for biotech start-ups as a over the course of her career, Olga has led teams to deliver 20 different clinical candidates, 3 drug launches, and several multi-year, multi-million dollar deals.
- **01.17.23 - Catalent Appoints Ricardo Zayas as North American Biologics Operations Leader ([PR](#))**
 - Mr. Zayas will be responsible for all of the company's North American biologics operations, including its centers of excellence for drug product fill/finish in Bloomington, Indiana, and gene therapy manufacturing in Harmans, Maryland. He will serve on the Executive Leadership Team, reporting directly to Catalent's President & Chief Executive Officer, Alessandro Maselli. Mr. Zayas' experience includes more than 30 years working in pharmaceutical manufacturing and operations leadership. He joins Catalent from Ocyonbio, a biosimilars, cell and gene, and viral vector development and manufacturing company, where he was Chief Operating Officer. Prior to that, as Executive Vice President and Head of Operations for Romark Pharmaceuticals, he led the development and buildout of Romark's new manufacturing facility in Puerto Rico. His career also includes seven years at Bristol-Myers Squibb, where he held the position of Senior Vice President, Global Pharmaceutical Manufacturing, Supply Chain, and Product Strategy, and led global pharmaceutical and API manufacturing, overseeing more than 8,000 employees worldwide.
- **01.12.23 - Senda Biosciences Appoints Luke O'Neill, Ph.D., as Chief Scientific Officer ([PR](#))**
 - Dr. O'Neill, a member of Senda's Board of Directors and Scientific Advisory Board, is the Chair of Biochemistry at Trinity College Dublin, and leads the college's Inflammation Research Group. His research focuses on the molecular basis of inflammation, with a concentration on innate immunity, toll-like receptors, inflammasomes, and metabolic reprogramming in macrophage activation. In 2018 and 2022, he was named by Clarivate/Thompson Reuters as one of the world's most influential scientists, ranking in the top 1% in immunology.
- **01.10.23 - NKGen Biotech Appoints Paul Y. Song, MD as Chief Executive Officer ([PR](#))**
 - Dr. Song has nearly 25 years of experience as a biopharma executive, clinician, and translational medicine expert. Most recently, Dr. Song served as Co-founder and CEO at FuseBio Therapeutics, a company developing immune modulating therapies for cancer. Prior to FuseBio he was Chief Medical Officer at NKMax America leading the NK cell therapy clinical program strategy; CMO at Cynvenio Biosystems, a clinical stage genomic peripheral blood monitoring company; and CMO/Senior Advisor for Berg Health. Before joining the pharmaceutical industry, Dr. Song was an attending physician at Cedars-Sinai Medical Center's Samuel Oschin Cancer Center.
- **01.10.23 - RoslinCT and Lykan Bioscience Announce the Appointment of Dr. Michael Mendicino to its Scientific Advisory Board ([PR](#))**
 - Dr. Mendicino brings 24 years of combined experience in academia, biotech, government, and consulting entities within the fields of Molecular & Cellular Biology & Genetics, and Immunology. He manages domestic and international projects and collaborations and is actively involved in due diligence and regulatory affairs. Dr. Mendicino is Founder, President and Chief Consultant at Hybrid Concepts International, LLC, a niche consulting firm focused on the cell and gene fields in a multi-disciplinary, one stop shop manner. Dr. Mendicino also co-founded a non-profit to support the cell and gene therapy industry. He has authored more than 20 publications and participated in multiple international conferences as a thought leader.
- **01.06.23 - Blueprint Medicines Appoints John Tsai, M.D. to its Board of Directors ([PR](#))**
 - Dr. Tsai joins the Board of Blueprint Medicines with more than 20 years of experience in bringing innovative therapies to market across geographies and therapeutic areas. Most recently, as President, Global Drug Development and Chief Medical Officer at Novartis AG, Dr. Tsai led the company's development portfolio spanning 160 new projects and 500 clinical trials as well as the team that secured global approvals for 15 new medicines including treatments using gene therapy, cell therapies, and new advanced platforms. Prior to joining Novartis in 2018, Dr. Tsai served as Chief Medical Officer and Senior Vice President of Global Medical Affairs at Amgen Inc. and spent 11 years at Bristol-Myers Squibbs.
- **01.05.23 - Kytopen Appoints Paul K. Wotton, Ph.D., to Chair of Board of Directors ([PR](#))**
 - New independent Board Chair, from 35+ year industry leader, an experienced CEO, Board Member, inventor, and serial entrepreneur. Dr. Wotton serves on the Board of Directors of Vericel Corporation and Cynata Therapeutics and is a Founder of Avenge Bio.

- 01.05.23 - Kytopen Appoints Paul K. Wotton, Ph.D., to Chair of Board of Directors ([PR](#))
 - New independent Board Chair, from 35+ year industry leader, an experienced CEO, Board Member, inventor, and serial entrepreneur. Dr. Wotton serves on the Board of Directors of Vericel Corporation and Cynata Therapeutics and is a Founder of Avenge Bio.
- 01.05.23 - Athersys Appoints Joseph Nolan to Its Board of Directors ([PR](#))
 - Athersys is a regenerative medicine company developing MultiStem® (invimestrocel) for critical care indications, announced the appointment of Joseph “Joe” Nolan to its Board of Directors. Mr. Nolan is an experienced biotechnology and pharmaceutical executive currently serving as Chief Executive Officer of Jaguar Gene Therapy, LLC. With this appointment, Athersys has five Directors, four of whom are independent. Mr. Nolan has particular expertise in launching products that treat central nervous system disorders, most in orphan and specialty settings. Before Jaguar, he was General Manager of AveXis (now Novartis Gene Therapies), where he was a part of the team that launched Zolgensma for the treatment of spinal muscular atrophy, one of two recently approved gene therapies in the U.S. Earlier in his career, Mr. Nolan served as President at Dohmen Life Science Services, Chief Commercial Officer at Marathon Pharmaceuticals and Chief Commercial Officer at Lundbeck Inc. He has also held senior positions at Takeda Pharmaceuticals and Abbott Laboratories.
- 01.03.23 - bluebird bio Appoints Joseph Vittiglio, JD, as Chief Business and Legal Officer ([PR](#))
 - Vittiglio joins bluebird from Finch Therapeutics Group, Inc., where he previously served as Chief Business and Legal Officer. At Finch, Vittiglio guided the company’s initial public offering in 2021, which raised \$130.8 million in capital, and led the company’s legal, business development, and quality teams. Prior to joining Finch, he was the General Counsel and Chief Business Officer for AMAG Pharmaceuticals Inc., where he led the company’s legal and business development initiatives, including oversight of the successful sale of the company to private equity investors, multiple out-licensing and partnership collaborations, and multiple therapeutic product launches.
- 01.03.23 - The Alliance for Regenerative Medicine Appoints Mark Battaglini as Chief Strategy Officer ([PR](#))
 - Mr. Battaglini will be responsible for ARM’s global policy, government affairs, communications, and alliance development activities. He will also lead the development of ARM’s strategy, mission, and vision, and guide the execution of the organization’s major priorities. Mr. Battaglini joins ARM after spending seven years at bluebird bio, culminating in his role as Senior Vice President of Global External Affairs and U.S. Government Payer, where he oversaw the global communications, patient advocacy, alliance development, public policy, government affairs, and state healthcare program functions. During his tenure at bluebird, he served on ARM’s Board of Directors and was a member of the government affairs committee at the American Society for Gene and Cell Therapy. Previously, he served in executive roles at Cubist Pharmaceuticals, Amylin Pharmaceuticals, Pharmacia Corporation, and Schering-Plough Corporation.

About Us:

Project Evolution is an innovative, end-to-end, HUMAN CAPITAL platform that enables leading Life Scientific organizations to identify and secure the talent required to drive innovation. Our collaborative platform is powered by the industry-leading capabilities of Berke Executive Search and GTS Scientific. The highly-successful Joint Venture bridge Executive and Contingent placement and enable organizations of all sizes the ability to secure highly specialized talent quickly and efficiently.



For More Information, Contact Bryan Kennedy at Bk@Projectevolution.org